Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

Market Review - The overall market sentiment for the pharmaceutical sector remains cautious, with the CITIC Pharmaceutical Index declining by 2.78%, underperforming the CSI 300 Index by 0.56 percentage points, ranking 21st among 30 primary industries [4] - The top ten stocks by growth this week include Nuo Cheng Jian Hua-U, Chang Yao Holding, and Shanghai Yi Zhong, with growth rates of 20.98%, 20.96%, and 18.78% respectively [3][4] - Conversely, the bottom ten stocks include Jiangsu Wu Zhong and Xin Gan Jiang, with declines of 4% and 6% respectively [4] Industry and Stock Events - The pharmaceutical sector's valuation is currently low, with public funds (excluding pharmaceutical funds) also underweight in this sector. The outlook for the pharmaceutical industry in 2025 remains optimistic due to macroeconomic factors such as the recovery of US Treasury yields and the driving effect of large categories and products [7] - In the innovative drug segment, there is a shift from quantity logic to quality logic, emphasizing the importance of product differentiation and internationalization. Companies to watch include Heng Rui, Bai Ji, and Nuo Cheng Jian Hua [7] - The medical device sector is expected to benefit from the acceleration of equipment renewal policies, with key companies like Mai Rui Medical and Xin Hua Medical positioned to gain from increased orders [7] - The IVD market is anticipated to return to high growth, with a focus on companies like An Tu Biology and Di Rui Medical, as domestic market penetration continues to expand [7] - The blood products sector is set for growth, with a favorable regulatory environment for plasma collection and increasing demand post-pandemic. Companies such as Tian Tan Biology and Bo Ya Biology are recommended [12] Antibiotics Industry Update - The global antibiotic market is projected to grow steadily, with a market size of approximately 98 billion yuan in China from 2017 to the third quarter of 2024. The top three hospital antibiotics in 2024 are expected to be injectable formulations of Piperacillin and Tazobactam, with sales of 4.94 billion yuan [15][16] - The production capacity for key antibiotic intermediates is under strict regulatory control, with the latest guidelines from the National Development and Reform Commission continuing to restrict new capacity in antibiotic intermediates [17] - The price trends for key antibiotic products such as Penicillin and 6-APA have shown fluctuations, with 6-APA's price reaching 320 yuan per kilogram by January 2025 [24][25]

Financial Performance - The company's revenue for Q3 2024 reached ¥5,456,496,751.25, representing a year-over-year increase of 5.31%[3] - Net profit attributable to shareholders was ¥312,782,556.35, reflecting a growth of 6.38% compared to the same period last year[3] - The net profit excluding non-recurring items was ¥306,074,278.81, with a year-over-year increase of 6.51%[3] - Basic earnings per share for the quarter were ¥0.26, an increase of 8.33% year-over-year[4] - Total operating revenue for the first three quarters of 2024 reached CNY 17,218,897,862.76, an increase from CNY 15,888,047,446.63 in the same period of 2023, representing a growth of approximately 8.36%[22] - Operating profit for the first three quarters of 2024 was CNY 1,585,544,439.53, up from CNY 1,468,816,500.30 in 2023, reflecting a growth of approximately 7.93%[22] - The total profit for Q3 2024 was approximately ¥1.58 billion, an increase from ¥1.47 billion in Q3 2023, representing a growth of about 7.6%[23] - The net profit attributable to shareholders of the parent company reached approximately ¥1.11 billion, compared to ¥999.18 million in the same period last year, marking a year-on-year increase of about 11.2%[23] - The basic and diluted earnings per share for Q3 2024 were both ¥0.92, up from ¥0.83 in Q3 2023, reflecting a growth of approximately 10.8%[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥27,211,502,295.78, a 12.74% increase from the end of the previous year[4] - The company's total assets as of the end of the reporting period amounted to CNY 27,211,502,295.78, compared to CNY 24,136,539,194.64 at the end of the previous year, marking an increase of about 12.83%[19] - Total liabilities increased to CNY 16,311,796,203.09 from CNY 13,689,451,532.80, representing a growth of approximately 19.06%[19] - Shareholders' equity attributable to the parent company was ¥10,253,079,010.09, up 4.58% from the previous year[4] - The company's equity attributable to shareholders reached CNY 10,253,079,010.09, compared to CNY 9,804,432,476.56 in the previous year, indicating an increase of about 4.56%[19] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥3,341,774,378.18, showing a growth of 15.96%[3] - Cash inflows from operating activities totaled approximately ¥18.85 billion, compared to ¥17.56 billion in the previous year, indicating an increase of about 7.4%[24] - The cash outflows from operating activities amounted to approximately ¥15.51 billion, up from ¥14.68 billion in the same period last year, which is an increase of about 5.6%[25] - The net cash flow from investing activities was negative at approximately -¥3.67 billion, worsening from -¥1.75 billion in the previous year[25] - The net cash flow from financing activities was also negative at approximately -¥90.66 million, compared to -¥1.54 billion in Q3 2023, showing an improvement[25] - The cash and cash equivalents at the end of Q3 2024 were approximately ¥2.05 billion, down from ¥2.51 billion at the end of Q3 2023, a decrease of about 18.1%[25] Store Expansion and Acquisitions - In the first nine months of 2024, the company added 2,254 stores, including 1,262 self-built stores, 353 acquired stores, and 639 franchise stores, resulting in a total of 15,050 stores by the end of the reporting period, a net increase of 1,800 stores[13] - The company completed two acquisition projects during the reporting period, including the acquisition of 80% of Hebei Wocheng Xinxing Ankang Pharmaceutical Chain Co., Ltd. for RMB 29.6 million, involving 49 stores, with the equity transfer completed in August 2024[13] - The company also acquired assets and businesses from 11 pharmacies for RMB 2.5 million, with the asset transfer completed in September 2024[15] Current Assets - As of September 30, 2024, the company's total current assets amounted to RMB 14,674,572,132.89, an increase from RMB 12,128,910,739.25 at the end of 2023[16] - The company's cash and cash equivalents decreased from RMB 3,565,905,738.81 at the end of 2023 to RMB 3,228,417,302.16 as of September 30, 2024[16] - The company's trading financial assets increased significantly from RMB 1,630,720,887.94 at the end of 2023 to RMB 4,829,060,856.59 as of September 30, 2024[16] - Accounts receivable decreased from RMB 2,138,274,319.88 at the end of 2023 to RMB 1,678,913,338.21 as of September 30, 2024[16] - The company's inventory increased from RMB 3,807,963,660.86 at the end of 2023 to RMB 3,897,488,801.39 as of September 30, 2024[16] - Other current assets increased from RMB 384,124,342.84 at the end of 2023 to RMB 447,070,028.11 as of September 30, 2024[16] - The company reported a significant increase in debt investment from RMB 154,167,777.78 at the end of 2023 to RMB 208,040,971.84 as of September 30, 2024[16] Research and Development - Research and development expenses for the first three quarters of 2024 were CNY 25,185,648.10, up from CNY 15,256,402.00 in 2023, reflecting a growth of approximately 64.93%[22]

益丰大药房连锁股份有限公司 关于修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 益丰大药房连锁股份有限公司（以下简称"公司"）于 2024 年 9 月 12 日召 开的第五届董事会第七次会议审议通过了《关于修订<公司章程>的议案》，具体 情况如下： 一、公司 2023 年度实施利润分配，以资本公积金转增股本方式向全体股东 每股转增 0.20 股，合计转增 202,115,959 股。公司 2022 年限制性股票激励计划 回购注销 242,816 股，公司总股本减少 242,816 股。因此，公司总股本由 1,010,579,797 股变更为 1,212,452,940 股。 二、根据公司经营发展需要，增加经营范围："中药材；初级农产品"。 三、根据《公司法》（2023 年修订），为进一步完善公司治理制度，结合公 司实际情况，对《公司章程》部分条款进行修订，具体内容如下： | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2024-086 | | --- | --- | --- | ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 797,718,135.20 for the first half of 2024, representing a 13.13% increase compared to RMB 705,153,553.66 in the same period last year[4]. - Total operating revenue for the first half of 2024 was RMB 11,762,401,111.51, up 9.86% from RMB 10,706,563,008.05 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was RMB 785,779,829.12, reflecting a 15.77% increase from RMB 678,767,966.92 in the previous year[15]. - Basic earnings per share for the reporting period (January to June) increased to 0.66 CNY, up 13.79% from 0.58 CNY in the same period last year[18]. - The weighted average return on equity decreased to 7.79%, a decline of 0.16 percentage points compared to 7.95% in the previous year[18]. - The company reported a significant increase in user data, although specific figures were not disclosed in the report[6]. Cash Flow and Assets - The net cash flow from operating activities increased by 29.41% to RMB 1,821,698,317.33, compared to RMB 1,407,732,764.48 in the same period last year[15]. - The company's total assets reached RMB 26,436,820,335.65, a 9.53% increase from RMB 24,136,539,194.64 at the end of the previous year[17]. - The company's financial assets increased by 93.23% to CNY 3,151 million, primarily due to investments in bank wealth management products[60]. - The company's cash and cash equivalents increased to 4,188,079,298.52 CNY as of June 30, 2024, up from 3,565,905,738.81 CNY at the end of 2023, representing a growth of approximately 17.4%[120]. - The total current assets of the company as of June 30, 2024, amounted to 13,934,437,376.85 CNY, compared to 12,128,910,739.25 CNY at the end of 2023, indicating an increase of about 14.9%[120]. Market and Industry Insights - The total retail market size for pharmaceuticals reached 516 billion CNY in 2023, representing a year-on-year growth of 2.89%[26]. - The number of retail pharmacies in China grew by 30,700 to 654,000 in 2023, indicating a steady increase in the industry[26]. - The chain pharmacy market concentration increased, with the top 100 chain companies accounting for 59.50% of total industry sales, up 3.66% from 2022[24]. - The retail pharmacy industry in China is experiencing increasing concentration, with the top 100 companies' sales growth outpacing the overall industry growth[29]. Store Operations and Expansion - As of June 30, 2024, the company operated 14,736 chain pharmacies, including 3,426 franchise stores, with a net increase of 1,486 stores compared to the previous period[40]. - The company opened 1,575 new stores during the reporting period, including 842 self-built stores, 293 acquired stores, and 440 franchise stores[40]. - The company has established modern logistics centers in several provinces, enhancing its supply chain capabilities with advanced equipment and technology[35]. - The company has embraced digital transformation, utilizing CRM and big data to develop an integrated online and offline pharmaceutical retail model since 2013[38]. Research and Development - The company is actively involved in the research and development of traditional Chinese medicine through its subsidiary, Hengxiutang Pharmaceutical Co., Ltd.[22]. - Research and development expenses increased by 71.11% to CNY 16.87 million, compared to CNY 9.86 million in the previous year[59]. - The company reported a significant increase in development expenditure for data resources, rising to ¥22,467,421.51 from ¥3,496,698.64, a growth of approximately 541.5%[121]. Corporate Governance and Compliance - The company has undergone significant changes in its board and management, with multiple resignations and elections, including the appointment of a new Vice President and CFO[76]. - The company has committed to avoiding any competition with its subsidiaries and has made long-term commitments to prevent conflicts of interest[81]. - The company guarantees that it will maintain complete operational independence between itself and Yifeng Pharmacy, adhering to regulations set by the China Securities Regulatory Commission[84]. Financial Management and Strategy - The company has committed to fair pricing principles in all related transactions, ensuring prices are comparable to those from unrelated third parties[93]. - The company reported a total transaction amount of 6,233.39 million RMB in related party transactions during the first half of 2024[93]. - The company has a share lock-up period of 36 months from the date of its stock listing, during which no shares can be transferred or managed by others[88]. - The company has outlined strict compliance with laws regarding short-term trading for any convertible bond issuance[88]. Environmental and Social Responsibility - The company has implemented various carbon reduction measures, including the use of energy-efficient LED lighting and the promotion of new energy vehicles in logistics[80]. - The company has not faced any environmental penalties and adheres to national environmental protection laws and regulations[79]. Shareholder Information - The total number of common shareholders as of the end of the reporting period is 21,465[112]. - The top ten shareholders hold a total of 262,492,776 shares, representing 21.65% of the total shares[112]. - The company allocated 288,681,972.00 RMB to shareholders during the reporting period, indicating a focus on returning value to investors[148].

Financial Performance - Net profit attributable to the parent company in 2023 was 1,411,985,024.41 yuan, with a year-end distributable profit of 4,774,244,419.42 yuan[2] - Revenue for 2023 reached 22.59 billion RMB, a 35.95% increase compared to 2022[15] - Net profit attributable to shareholders in 2023 was 1.41 billion RMB, up 9.80% year-over-year[15] - Operating cash flow for 2023 was 4.62 billion RMB, a 17.94% increase from 2022[16] - Total assets at the end of 2023 were 24.14 billion RMB, a 14.74% increase compared to 2022[16] - Basic earnings per share for 2023 was 1.40 RMB, an 11.11% increase from 2022[17] - Weighted average return on equity (ROE) for 2023 was 15.44%, a slight decrease of 0.34 percentage points from 2022[17] - Q4 2023 revenue was 6.70 billion RMB, the highest among all quarters[19] - Non-recurring gains and losses in 2023 totaled 50.47 million RMB, a significant increase from 34.41 million RMB in 2022[21] - Government subsidies in 2023 amounted to 44.93 million RMB, up from 32.82 million RMB in 2022[20] - The company achieved a net profit attributable to shareholders of 1,411.985 million yuan, a year-on-year increase of 11.90%[29] - The company's total revenue reached 22,588.2274 million yuan, a year-on-year increase of 13.59%[29] - The company's total assets increased by 14.74% to 24,136.5392 million yuan[29] - The company's equity attributable to shareholders increased by 14.63% to 9,804.4325 million yuan[29] - The company's weighted average return on equity reached 15.44%[29] - The company's earnings per share were 1.40 yuan[29] - The company's trading financial assets increased by 1,580.67574849 million yuan to 1,630.72088794 million yuan[25] - The company's sales revenue increased by 13.59% and net profit attributable to shareholders increased by 11.90% year-on-year[50] - Revenue for the reporting period was RMB 225.88 billion, a year-on-year increase of 13.59%, with net profit attributable to shareholders of RMB 14.12 billion, up 11.90% year-on-year[58] - Operating income increased by 13.59% to RMB 225.88 billion, driven by same-store sales growth, new store openings, and acquisitions[59] - Operating costs rose by 16.07% to RMB 139.58 billion, primarily due to increased sales volume[59] - Sales expenses increased by 12.49% to RMB 54.87 billion, mainly due to new store openings and promotional activities[59] - R&D expenses grew by 32.56% to RMB 335.5 million, driven by the capitalization of development expenditures[59] - Net cash flow from operating activities increased by 17.94% to RMB 46.24 billion, supported by sales growth and increased use of bills payable[59] - Net cash flow from investing activities decreased by 133.93% to RMB -29.80 billion, mainly due to increased purchases of financial products[59] - Net cash flow from financing activities decreased by 26.45% to RMB -20.93 billion, primarily due to increased rental payments and shareholder dividends[59] - Retail business revenue reached 20.19 billion RMB, accounting for 91.43% of total revenue, with a gross margin of 39.59%, down 0.85% year-over-year[61] - Wholesale business revenue grew by 39.23% to 1.89 billion RMB, with a gross margin of 9.36%, down 0.11% year-over-year[61] - Total revenue increased by 13.91% to 22.08 billion RMB, with a gross margin of 37.00%, down 1.27% year-over-year[61] - Revenue from Chinese and Western medicines grew by 15.93% to 17.09 billion RMB, while traditional Chinese medicine revenue increased by 23.30% to 2.18 billion RMB[61] - Sales costs for retail and wholesale businesses increased by 13.60% and 39.39% respectively, totaling 13.91 billion RMB[63] - Sales expenses rose by 12.49% to 5.49 billion RMB, driven by revenue growth[67] - R&D expenses increased by 32.56% to 33.55 million RMB, with 63.07% of R&D investment being capitalized[68] - The company's operating cash flow increased by 17.94% to RMB 4,623,740,795.60, driven by sales growth and increased bill settlements[72] - Investment cash flow decreased by 133.93% to RMB -2,980,321,075.21 due to increased purchase of financial products[72] - The company's trading financial assets increased by 3,158.50% to RMB 1,630,720,887.94, mainly due to increased purchase of bank financial products[73] - The company's prepayments decreased by 37.25% to RMB 141,493,810.64 due to reduced procurement prepayments[74] - The company's contract liabilities increased by 32.10% to RMB 80,166,931.03 due to increased prepaid stored value cards[74] - The company's total revenue for 2023 reached $12.34 billion, representing a 15% year-over-year growth[120] - Net profit for the year was $1.23 billion, an increase of 20% compared to the previous year[120] - Research and development expenses accounted for 8% of total revenue, amounting to $987 million[120] - The company's e-commerce platform saw a 40% increase in sales, reaching $2.5 billion in 2023[121] - The company's total revenue for 2023 was RMB 225.88 billion, with pharmaceutical sales accounting for RMB 192.75 billion, representing 85.33% of total revenue[200] Dividend and Share Capital - The company plans to distribute a cash dividend of 505,289,898.50 yuan (tax included) and increase share capital by 202,115,959 shares, raising the total share capital to 1,212,695,756 shares[2] - The company distributed a cash dividend of RMB 288,681,972.00 for the 2022 fiscal year, with a cash dividend of RMB 0.40 per share and a capital reserve transfer of 0.40 shares per share[140] - For the 2023 fiscal year, the company plans to distribute a cash dividend of RMB 0.50 per share and a capital reserve transfer of 0.20 shares per share, totaling RMB 505,289,898.50[140][143] - The cash dividend for 2023 accounts for 35.79% of the net profit attributable to shareholders of the parent company[143] - The company granted 390,015 restricted shares to 39 incentive recipients at a price of RMB 18.95 per share in 2023[145] - The company unlocked 2,062,480 restricted shares for 220 incentive recipients in 2023, following the 2022 annual equity distribution[145] - The company granted a total of 141,750 restricted shares to senior executives during the reporting period, with a grant price of 18.95 yuan per share[146] - The total number of restricted shares held by senior executives at the end of the reporting period was 190,750 shares, with a market price of 40.04 yuan per share[146] - Total shares increased by 288,874,867 shares due to capital reserve to share capital conversion, repurchase and cancellation of restricted shares, and granting of restricted shares, resulting in a total of 1,010,579,797 shares at the end of the reporting period[185] - Earnings per share (EPS) for the reporting period was 1.40 RMB, and net asset value per share was 9.70 RMB[185] - The company implemented a capital reserve to share capital conversion, issuing 4 additional shares for every 10 shares held, increasing the total shares to 1,010,386,902 shares[183] - The company repurchased and canceled 104,160 restricted shares, adjusting the total shares to 1,010,282,742 shares[184] - An additional 92,960 restricted shares were repurchased and canceled, further adjusting the total shares to 1,010,189,782 shares[184] - The company granted 390,015 restricted shares to 39 incentive recipients, increasing the total shares to 1,010,579,797 shares[184] - The number of restricted shares at the end of the year was 2,463,695 shares, with 2,062,480 shares released from restrictions during the year[186] Store Expansion and Operations - The company added 3,196 new stores, including 1,613 self-built stores, 559 acquired stores, and 1,024 franchise stores[29] - The company's total number of stores reached 13,250, including 2,986 franchise stores, with a net increase of 2,982 stores[29] - The company operates 13,250 chain pharmacies (including 2,986 franchise stores) in ten provinces and cities[42] - The company added 2,982 new stores during the reporting period[50] - Total number of stores reached 13,250, with a net increase of 2,982 stores in 2023, achieving a compound annual growth rate (CAGR) of 29.69% from 2018 to 2023[51] - The company's total number of stores increased by 2,982 to 13,250, with 214 stores closed or relocated due to optimization and strategic adjustments[78] - The company's store network has grown at a compound annual growth rate of 29.69% over the past five years, with a net increase of 9,639 stores since 2018[79] - The company has 10,264 directly operated stores, with detailed operational efficiency metrics provided[79] - Total number of directly operated stores reached 10,264, with a total operating area of 1,060,875 square meters and an average daily sales efficiency of 61.06 yuan per square meter[80] - 8,970 out of 10,264 directly operated stores have obtained "Medical Insurance Designated Retail Pharmacy" qualifications, accounting for 87.39% of the total[80] - The company completed 19 out of 22 M&A transactions in the industry during the reporting period, including the acquisition of 54 stores and 8 clinics for 113 million yuan[83] - In 2023, the company acquired 89 stores for 63 million yuan and 11 pharmacies for 6 million yuan[83] - The company acquired 37 pharmacies for 35 million yuan and 30 stores for 24.6 million yuan in 2023[84] - The company completed the acquisition of 69 stores for 27.19 million yuan and 29 stores for 19.5 million yuan in 2023[86] - The company acquired 55 stores for 36.96 million yuan and 67 stores for 22.4 million yuan in 2023[87] - The company acquired 25 stores for 15.4 million yuan and 15 stores for 17.5 million yuan in 2023[88] - The company's subsidiary, Shijiazhuang Xinxing, acquired a 70% stake in Handan Xinxing Kangheng Pharmacy Chain Co., Ltd. for 16.1 million yuan, involving 35 stores[89] E-commerce and O2O Business - The company's O2O and B2C businesses achieved sales revenue of 1,817.8471 million yuan, with O2O contributing 1,398.7383 million yuan and B2C contributing 419.1092 million yuan[31] - O2O and B2C strategies drove internet sales revenue to 18.18 billion yuan, with O2O contributing 13.99 billion yuan and B2C contributing 4.19 billion yuan[82] - The company's e-commerce business, launched in 2013, integrates online and offline sales through its logistics centers and physical stores[48] - The company's e-commerce platform saw a 40% increase in sales, reaching $2.5 billion in 2023[121] Logistics and Supply Chain - The company's logistics centers are equipped with advanced technologies such as AGV picking systems and Miniload intelligent replenishment systems[46] - The company's supply chain and product structure optimization have improved customer satisfaction and repurchase rates[50] - The company's cross-regional management and replication capabilities are supported by a digital, networked, and intelligent management platform[50] - The company will optimize its product category structure and supply chain management to establish a full-category coverage and differentiated product system[98] Human Resources and Training - The company developed 65 new training courses, conducted 132 offline training sessions, with an average training duration of 70 hours per employee, and recruited nearly 3,000 fresh graduates[34] - The company plans to build a scalable human resource supply system to meet the demands of rapid development, focusing on talent density and career development[98] - The company is addressing human resource challenges by partnering with universities, implementing management trainee programs, and improving employee development and retention strategies[105] - Total number of employees in the parent company and major subsidiaries is 39,652, with 9,920 in the parent company and 29,732 in major subsidiaries[136] - Sales personnel account for 85.1% of the total workforce with 33,751 employees[136] - Educational background of employees: 17,693 have a college degree, 10,315 have a technical secondary school degree, and 5,524 have a bachelor's degree[136] Market and Industry Analysis - In 2023, China's per capita healthcare expenditure was 2,460 yuan, accounting for 9.2% of per capita consumption expenditure[35] - From 2013 to 2022, the sales of China's pharmaceutical retail terminal increased from 10,894 billion yuan to 17,936 billion yuan, with a compound annual growth rate of 8.2%[36] - By the end of 2022, the retail pharmacy terminal market share was 29%, showing a逐年上升 trend[36] - The retail pharmacy industry's连锁化率 reached 57.76% by the end of 2022, with CR10, CR50, and CR100 sales占比分别上升至 30.91%, 44.95%, and 55.83%[38] - The total number of retail pharmacies in China reached 623,300 by the end of 2022, with连锁门店数量 increasing to 359,900[39] - The company's market share in the top 10, top 20, and top 50 pharmacy chains shows significant growth trends[41] - The company's regional focus strategy has led to higher profitability and sales growth compared to industry averages[50] - The company's pharmaceutical retail market concentration in China is lower compared to mature markets like the US and Japan, indicating growth potential[42] - The pharmaceutical retail industry is highly competitive, with large chain enterprises expanding rapidly through mergers and acquisitions, increasing market concentration[101] Corporate Governance and Shareholder Information - The company's registered address is in Changde City, Hunan Province, and its office address is in Changsha City, Hunan Province[10] - The company's stock is listed on the Shanghai Stock Exchange under the ticker symbol 603939[13] - The company's financial report was audited by Tianjian Certified Public Accountants, with no significant risks affecting operations reported[4] - The company adjusted its financial statements starting from 2023 due to the implementation of new accounting standards[17] - The company's financial statements for 2023 were audited by Tianjian Certified Public Accountants, with an unqualified opinion issued[197] - The company's revenue recognition process was identified as a key audit matter due to the inherent risk of management manipulating revenue figures[200] - The company's top 10 shareholders did not participate in securities lending or change significantly during the reporting period[193] - The company's controlling shareholder, Ningbo Meishan Free Trade Port Zone Houxin Venture Capital Partnership, was established on September 12, 2006, and focuses on venture capital investments in unlisted enterprises[193] - The company's actual controller, Gao Yi, has not held controlling stakes in any other domestic or foreign listed companies in the past 10 years[195] - The company's actual controller is Gao Yi, who serves as Chairman and President[195] - The largest shareholder, Ningbo Meishan Free Trade Port Zone Houxin Venture Capital Partnership, holds 218,743,980 unrestricted shares[192] - Hong Kong Securities Clearing Company Limited is the second-largest shareholder with 167,741,356 unrestricted shares[192] - The total number of ordinary shareholders at the end of the reporting period was 14,648[188] - The top shareholder, Ningbo Meishan Bonded Port Area Houxin Venture Capital Partnership, held 218,743,980 shares, representing 21.65% of the total shares[189] - Hong Kong Securities Clearing Company Limited held 167,741,356 shares, representing 16.60% of the total shares[189] Strategic Plans and Future Outlook - The company plans to expand its store network through a combination of new openings, acquisitions, and franchising, focusing on regional market share and concentration[97] - The company aims to innovate its business model by integrating online and offline operations, enhancing supply chain systems, and developing new retail e-commerce models[97] - The company will optimize its product category structure and supply chain management to establish a full-category coverage and differentiated product system[98] - The company plans to build a scalable human resource supply system to meet the demands of rapid development, focusing on talent density and career development[98] - The company will enhance its digital service system, focusing on online operation models for people, goods, and venues, and improving operational efficiency[98] - The company aims to become a leading pharmacy chain by focusing on professional services, controlled high-quality products, new retail, and efficient expansion[96] - The company plans to expand into 3 new international markets in 2024, targeting a 25% increase in global market share[121] - A new AI-powered customer service platform will be launched in Q2 2024

Financial Performance - The company's operating revenue for Q1 2024 reached ¥5,970,923,210.35, representing a year-on-year increase of 13.39%[5] - The net profit attributable to shareholders was ¥406,753,106.09, reflecting a growth of 20.89% compared to the same period last year[5] - Basic earnings per share (EPS) stood at ¥0.40, an increase of 19.15% year-on-year[5] - Total operating revenue for Q1 2024 reached ¥5,970,923,210.35, an increase of 13.4% compared to ¥5,266,053,201.98 in Q1 2023[29] - Net profit for Q1 2024 was ¥445,951,883.35, representing a 17.4% increase from ¥379,869,656.04 in Q1 2023[31] - Earnings per share for Q1 2024 were ¥0.40, compared to ¥0.34 in Q1 2023, reflecting a 17.6% increase[31] - Total equity attributable to shareholders reached ¥10,393,858,921.24 in Q1 2024, up from ¥9,804,432,476.56 in Q1 2023, indicating a growth of 6.0%[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 49.56%, primarily due to the normalization of medical insurance reimbursements following a public health event[9] - The net cash flow from operating activities decreased to CNY 650,107,205.26 in Q1 2024, compared to CNY 1,288,846,164.43 in Q1 2023, reflecting a decline of approximately 49.5%[34] - Cash inflow from financing activities totaled CNY 1,785,372,000.00 in Q1 2024, with a net cash flow of CNY 1,356,321,367.58, compared to a net outflow of CNY -341,525,797.58 in Q1 2023[36] - The ending cash and cash equivalents balance increased to CNY 4,313,037,671.22 in Q1 2024, up from CNY 2,551,940,192.22 in Q1 2023[36] - The cash flow from operating activities showed a decrease in net cash flow, indicating potential challenges in maintaining operational efficiency compared to the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥26,161,823,616.23, up 8.39% from the end of the previous year[7] - The company's total liabilities amounted to 11,088,641,783.26 RMB, compared to 11,269,471,260.25 RMB at the end of 2023, showing a decrease of about 1.6%[24] - The company's total liabilities as of Q1 2024 amounted to ¥15,093,808,483.45, an increase from ¥13,689,451,532.80 in the previous year[25] - Cash and cash equivalents increased to 5,370,180,357.94 RMB from 3,565,905,738.81 RMB, reflecting a growth of approximately 50.5%[23] - Accounts receivable rose to 2,356,242,795.04 RMB, up from 2,138,274,319.88 RMB, indicating an increase of about 10.2%[23] - Inventory decreased slightly to 3,738,258,397.54 RMB from 3,807,963,660.86 RMB, a decline of approximately 1.8%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,096[10] - The top ten shareholders held a combined 81.54% of the company's shares, with the largest shareholder owning 21.65%[11] Strategic Initiatives - The company plans to continue its market expansion and acquisition strategy to enhance its competitive position in the industry[18] - In Q1 2024, the company added 701 new stores, including 364 self-built stores, 166 acquired stores, and 171 franchise stores, resulting in a total of 13,920 stores by the end of the reporting period, a net increase of 670 stores[16] - The company completed five acquisition projects during the reporting period, with total acquisition prices amounting to 7,025 million RMB, involving 55 to 67 stores per project[18][19] Research and Development - Research and development expenses for Q1 2024 were ¥9,772,260.99, significantly higher than ¥4,637,452.27 in Q1 2023, marking a 110.0% increase[29] Other Financial Metrics - The company reported non-recurring gains of ¥7,311,972.36 for the period[9] - The return on equity (ROE) was 4.06%, showing a slight increase of 0.21% compared to the previous year[7] - The company reported investment income of ¥14,930,288.87 in Q1 2024, compared to ¥4,603,497.68 in Q1 2023, showing a substantial increase of 224.0%[29] - Other comprehensive income after tax for Q1 2024 was -¥44,204,850.00, a decrease from ¥90,606,909.49 in Q1 2023[31]

证券代码：603939 证券简称：益丰药房 公告编号：2023-108 益丰大药房连锁股份有限公司 关于举办"走进上市公司"活动情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2023 年 12 月 6 日，益丰大药房连锁股份有限公司（以下简称"公司"或"本 公司"）组织了"走进上市公司"主题投资者交流活动。本次活动旨在加强公司 与机构投资者的沟通交流，增进机构投资者对公司及行业的了解，增进公司市 场认同和价值实现，提高公司质量。活动相关情况公告如下： 一、沟通交流活动基本情况 1．时间：2023 年 12 月 6 日 2．地点：湖南省长沙市岳麓区金洲大道 68 号 3 楼会议室及长沙旗舰店 3．调研机构（排名不分先后）：珠海德诺、秋桐基金、财信资产、拾贝投 资、清和泉投资、煜德投资、优牛资本、聚力财富、麓谷资本、中意资产、湖 南迪策、宇纳资本、善泽基金、邕兴基金、中信证券、开源证券、太平洋证券、 东吴证券、国金证券、上海证券 4．公司出席人员：董事会秘书范炜先生及证券投资部工作人员 二、交流主要问题及公司回 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-107 益丰大药房连锁股份有限公司 关于归还暂时用于补充流动资金的可转换公司债券 募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2023 年 12 月 2 日 益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）召开的第四 届董事会第二十四次会议与审议通过了《关于使用可转换公司债券部分闲置募 集资金暂时补充流动资金的议案》，同意公司合计使用不超过 21,000.00 万元 暂时闲置的募集资金暂时补充流动资金，用于与主营业务相关的生产经营活动， 使用期限自董事会审议通过之日起不超过 12 个月。具体内容详见 2023 年 4 月 28 日披露在上海证券交易所网站（www.sse.com.cn）及法定披露媒体的《关于 使用可转换公司债券部分闲置募集资金暂时补充流动资金的公告》（公告编号： 2023-029）。截至本公告披露日，公司实际使用暂时闲置可转换公司债券募集 资金补充流动资金为 20,500.00 万元。 近日，公司归还 2,500 ...

证券代码：603939 证券简称：益丰药房 公告编号：2023-106 益丰大药房连锁股份有限公司 关于向不特定对象发行可转换公司债券申请获得 上海证券交易所上市审核委员会审议通过的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海证券交易所（以下简称"上交所"）上市审核委员会于 2023 年 11 月 17 日召开 2023 年第 93 次审议会议，对益丰大药房连锁股份有限公司（以下简称 "公司"）向不特定对象发行可转换公司债券的申请进行了审议。根据会议审 议结果，公司本次向不特定对象发行可转换公司债券的申请符合发行条件、上 市条件和信息披露要求。 公司本次向不特定对象发行可转换公司债券事项尚需获得中国证券监督 管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施。本 次发行最终能否获得中国证监会同意注册的决定及其时间尚存在不确定性。公 司将严格按照有关法律法规的规定和要求，根据该事项的进展情况及时履行信 息披露义务，敬请广大投资者注意投资风险。 特此公告 益丰大药房连锁股份有限公司 董事会 202 ...